In April of this year, Bain and the Medical Industry Private Equity Capital Association (HCPEA) jointly released a research report on the 2014 private research market in the medical industry. (Note: Bain is a leading global management consulting firm that provides clients with strategic consulting services in strategy, operations, technology, organization and M&A based on the concept of “Consultants provide results to customers, not reportsâ€. HCPEA is a non-profit trading association. Members of the association are committed to the long-term development of the medical and health industry. More than 50 companies are the most famous and respected private equity firms, employing more than 300 investment experts from the US and Canada. More than US$100 million, the investment targets are related to the medical industry, including services, products, diagnostics, medicine and IT.) Reviewing the 2014 private market for the medical industry Highlights: 1 The transaction amount hit a new high in three years, but the transaction volume decreased, and the asset size was not large enough to meet the needs of investors. 2 The enthusiasm for investment and entrepreneurship in Europe continues to heat up, thanks to four big deals. 3 Due to the spin-off of several large companies, the value of transactions in medical technology has soared 4 Investors insist that the previous investment strategy remains unchanged The medical industry is in the midst of an industry transition. The world is generally curbing medical expenses and changing the trend of sustained high growth in the medical industry in previous years. At present, medical companies have seen unprecedented inter-company mergers and acquisitions. This strategic M&A transaction amount is nearly 380 billion US dollars, reaching the highest level in history. For companies interested in private equity investments in the healthcare sector, the industry situation is complex in 2014. New healthcare purchases worldwide hit a three-year high of $29.6 billion, almost double the number in 2013, and the number of transactions fell 10% to 188 (Figure 1). More than $4 billion in two huge transactions and medium-sized transactions (between $500 million and $1 billion) have led to an increase in total transaction volume; however, similar to 2013, only five transactions exceeded $1 billion. Off, so 2014 is a challenging year for investors who want to spend a lot of money (Figure 2). In addition, strong public equity markets and unstoppable strategic buyers continue to push up valuations, which has eroded the buying enthusiasm of some investors, even when the seller's expectations of high valuations are not met, resulting in the acquisition of abortion. The positive side of this trend is the formation of a good capital exit environment, which is equivalent to the level of 2013 in 2014. figure 1 figure 2 By region, the European market is active, ranking fourth in the world in 2014, but it also lacks large-scale asset transactions, with only three pens exceeding $1 billion. Similarly, although the volume of transactions in North America is huge, it is worth noting that the region has long lacked large-scale, reasonably priced assets as investment targets. In the Asia Pacific region, the level of activity is different. China is a bright spot. Due to the introduction of regulations favorable to foreign investors, India's private equity market tends to ease compared to 2013. According to the field, medical technology and related services are the most concerned. The spin-off of large-scale enterprises has greatly increased the transaction volume, and the total value will be five times that of 2013. Diagnosis remains the most popular area and has a high level of interest in both Chinese and developed markets. In the biopharmaceutical and related services sector, transaction value and transaction volume have declined compared to 2013; the most notable in the sub-sector are contract outsourcing organizations (CXO), over-the-counter (OTC) and generic drug manufacturers. Medical service providers and related services have also performed well, while capital has a strong interest in multi-asset product suppliers and emerging markets. In 2014, many investment strategies continued. The products and services pursued by investors were “heavy medical care†and “light health careâ€. Some funds pursued “gemstone†assets with sufficient safety, or assets with absolute leadership in their core markets. Although the transaction price is at a steep high, investors believe this will accelerate fund turnover. Due to the lack of large-scale transactions, some funds have turned to the downstream market and will invest in projects in the early stages of the venture. Finally, the purchase restructuring strategy is still mainstream in 2014, with some companies continually refining previously acquired assets and others acquiring new platforms. Private placement of medical industry in different regions I. Overview Highlights: 1 In terms of volume, medical service supply is still the most popular in all regions. 2 The turnover of all regions increased, and the volume of transactions decreased. 3 The largest transaction volume is concentrated in Europe and North America, with the largest transaction volume in Brazil 4 Asia Pacific Rim is very active in both developing and developed markets Like last year, a large amount of private funds poured into North America and Europe, and South America is also on the list, mainly because Bain Capital's nearly $860 million acquisition of health insurer and healthcare provider Intermédica Sistema de Saúde. In fact, the low valuation of Brazilian assets has caused many private equity funds to return to Brazil. Asia and the Pacific Rim are as stable as the market in 2013 and remain strong. The volume of acquisitions in all regions has declined and the value of the transaction has increased (Figure 3), which is in line with historical trends, and the field of medical service provision has revitalized most of the global business market. A notable change in 2014: medical technology transaction value and transaction volume increased in Europe and North America, and the corresponding biopharmaceutical sector declined (Figure 4). Medical technology is popular in China, largely because of changes in regulatory policies. image 3 Figure 4 Fresh Frozen Squid ring Squid Ring,Frozen Squid Ring,Fresh Frozen Squid Ring,Delicious Fresh Frozen Squid Ring Zhoushan Junwei Aquatic Products Co., Ltd. , https://www.junweiaquatic-intl.com
